PDCD1 and cancer: Cancer cells evade immune surveillance by expressing inhibitory molecules such as programmed death-ligand 1 (PD-L1), which interacts with the programmed cell death protein 1 (PD-1) receptor on T-cells, effectively shutting down their anti-tumor activity.